Investigation into the efficacy of Chlorpromazine as a second line therapy for Cannabis Hyperemesis.

Prospective randomised single-blind trial to determine whether standard antiemetic treatment plus chlorpromazine is more effective in reducing episodes of vomiting in patients who present acutely with cannabinoid hyperemesis than standard antiemetic treatment alone.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000573257

Enrollment

Registered

2009-07-14

Start date

2009-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to identify whether the use of chlorpromazine is more effective than standard therapy at treating vomiting associated with Cannabis Hyperemesis Syndrome. The cause of this condition is unknown but similar syndromes of Adult Cylclical vomiting are thought to be related to migraines. Chlorpromazine has been chosen because it is both an antiemetic and anti-migraine therapy.

Interventions

A single dose of metaclopramide 10mg intravenous (iv) and tropisetron 2mg Intravenous (iv) given to all patients in trail. A single dose of Chlorpromazine 25mg in normal saline 1L intravenous (iv) given to treatment group.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

16 Years to 99 Years

Healthy volunteers

Inclusion criteria

Intractable vomiting in patients with known cannabis use and no other pathological cause identified. Informed consent given.

Exclusion criteria

Declined consent. Previous participation Grossly abnormal observations or signs of serious pathology. Pregnancy Allergy to chlorpromazine Concurrent use of any drug which is contraindicated with chlorpromazine

Outcome results